# CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

> **NCT01202409** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Gastrointestinal Cancer

## Interventions

- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT01202409
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-02
- **Primary completion:** 2018-07-03
- **Final completion:** 2018-07-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202409, "CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01202409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*